Protagonist Therapeutics (PTGX) Operating Income: 2017-2025
Historic Operating Income for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$46.4 million.
- Protagonist Therapeutics' Operating Income fell 11.98% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 87.25%. This contributed to the annual value of $252.8 million for FY2024, which is 369.98% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Operating Income is -$46.4 million, which was down 10.42% from -$42.0 million recorded in Q2 2025.
- Protagonist Therapeutics' Operating Income's 5-year high stood at $206.3 million during Q1 2024, with a 5-year trough of -$46.4 million in Q3 2025.
- Over the past 3 years, Protagonist Therapeutics' median Operating Income value was -$38.3 million (recorded in 2023), while the average stood at $4.7 million.
- Its Operating Income has fluctuated over the past 5 years, first slumped by 336.52% in 2021, then surged by 672.75% in 2024.
- Protagonist Therapeutics' Operating Income (Quarterly) stood at -$37.0 million in 2021, then rose by 1.35% to -$36.5 million in 2022, then soared by 163.12% to $23.0 million in 2023, then soared by 450.05% to $126.8 million in 2024, then fell by 11.98% to -$46.4 million in 2025.
- Its last three reported values are -$46.4 million in Q3 2025, -$42.0 million for Q2 2025, and -$19.3 million during Q1 2025.